FDA Warning Letter Recap
Feedback Sought On Proposals To Improve Australia’s Recall Processes
The deadline is nearing for comments on changes the Therapeutic Goods Administration has proposed making to its therapeutic products recall processes.
Warning Letters And Close-Outs – February 2023
The US FDA released three device-related closeout letters in February, resolving past citations against BioModeling Solutions, Sooil Development Co., and USA Medical LLC. No new warning letters were issued.
News We’re Watching – Medicare Covers Dexcom CGM; New Mpox EUA; $106M Patent Verdict Against Medtronic
Medicare announced coverage for the Dexcom G7 continuous glucose monitor, as well as a breast cancer indication for Natera Inc.’s Signatera; the FDA authorized a new monkeypox test; the FDA issued a warning letter to a Texas masks firm; and a new report says NIST labs are failing behind.
Warning Letter Close-Outs – January 2023
The US FDA released only one device-related close-out letters in January which went to a Michigan orthopedics firm.
Warning Letter Roundup & Recap – January 2023
The US Food and Drug Administration published three device-related warning letters in January – two that went to divisions of endoscope vendor Olympus, and one to a Maryland vision treatment firm.
FDA Issues Back-To-Back Warnings To Major Endoscope Maker Amid Device Reporting And Quality Systems Concerns
The US Food and Drug Administration issued warning letters in 2022 to Japanese device maker Olympus Medical Systems Corporation and a subsidiary concerning good manufacturing practices related to its endoscopes.
Texas OTC Medtech Firm Refuses FDA Inspection, Continues Selling Unapproved Products
RoyalVibe Health makes and sells unapproved devices in kits and individually “intended for the diagnosis and treatment of several diseases including but not limited to cancer, Alzheimer’s, ischemic stroke, arthritis, and type 1 diabetes,” FDA warning states.
Warning Letter Roundup & Recap – December 2022
The US Food and Drug Administration published two device-related warning letters in December, both of which went to marketers of products not authorized by the agency.
Warning Letter Close-Outs – December 2022
The US FDA released only one device-related close-out letters in December, which went to the maker of a tray used to flash sterilize devices.
Warning Letter Close-Outs – November 2022
The US FDA released three device-related close-out letters in November, all of which related to premarket conduct.
Warning Letter Roundup & Recap – November 2022
The US Food and Drug Administration published only one device-related warning letter last month. It went to an Illinois clinical trial site.
FDA Warns Eye Care Company Conducting Unapproved Clinical Trial Of Drug-Device Product
The FDA sent a warning letter to Arbor Center for EyeCare for failing to submit an IND before beginning a trial of a novel drug-device combination product.
All set! This article has been sent to firstname.lastname@example.org.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
Please Note: Only individuals with an active subscription will be able to access the full article. All other readers will be directed to the abstract and would need to subscribe.